Asthma Clinical Trial
Official title:
A Randomized, Placebo-Controlled, Double-Blind Pilot Study of Pioglitazone Hydrochloride in Allergic Asthma
Verified date | October 30, 2009 |
Source | National Institutes of Health Clinical Center (CC) |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This study will test whether pioglitazone hydrochloride (Actos (Registered Trademark)
Registered Trademark) is effective for treating patients with asthma who do not respond to
standard therapy. Experiments have shown that this drug, which is used to treat patients with
diabetes, may be effective for treating asthma.
People between 18 and 75 years of age who have had asthma for at least a1 year and whose
symptoms are not well controlled with high doses of inhaled corticosteroids with or without
long-acting bronchodilators may be eligible for this study. Candidates are screened with
breathing tests, an allergy skin test, chest x-ray, electrocardiogram (ECG), echocardiogram
(ultrasound test of the heart), blood tests, and DEXA scan (an x-ray to measure bone
thickness) to make sure they are eligible for the study.
Then, participants undergo tests and procedures in the following study phases:
Phase 1
Participants are given a device to measure and record their lung function and asthma symptoms
at home each morning and night for 4 weeks before starting the study medication. Lung
function is also measured at clinic visits before and after inhaling a bronchodilator
medicine. Before starting the study medication, participants have a sputum induction (sputum
collection test). For this test, the participants inhale a salt-water mist and are asked to
collect sputum into a plastic cup.
Phase II
Participants are randomly selected to receive either pioglitazone hydrochloride or placebo (a
look-alike pill with no active ingredient) once a day for 10 weeks. They return to the clinic
after 2 weeks to repeat the tests done in Phase 1 and to monitor any reactions to the study
drug or placebo. If there are no problems, the amount of medication is increased once, and
then they return for follow-up evaluations every 2 weeks for 8 weeks. Pulmonary function
tests, sputum collection and DEXA scan are repeated after 10 weeks on medication.
Phase III
Patients return for follow-up 1 month after stopping the medication or placebo to monitor
their asthma.
Status | Withdrawn |
Enrollment | 0 |
Est. completion date | October 30, 2009 |
Est. primary completion date | October 30, 2009 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 75 Years |
Eligibility |
- INCLUSION CRITERIA: Patients will be between 18 and 75 years of age, male or female, with a diagnosis of asthma for at least one year. Patients must have reversible airflow obstruction as defined by a positive methacholine bronchoprovocation challenge or a positive response to inhaled bronchodilators. Patients must be treated with EPR-3 Step 5 therapy (high dose (great than or equal to 440 ucg/day) fluticasone inhaler or equivalent dose of another inhaled corticosteroid) with or without an inhaled long-acting beta-2-agonist) for at least 3 months. Patients must meet the EPR-3 criteria for not well controlled asthma. The EPR-3 definition for not well controlled asthma includes any of the following features in a week (unless otherwise indicated): daytime asthma symptoms great than 2 days/week, limitation of activities, nocturnal symptoms or awakening greater than 2 times/month, need for reliever/rescue treatment greater than 2 days/week, PEF or FEV(1) less than 80% predicted. Pre-bronchodilator FEV(1) greater than or equal to 55% of predicted and post-bronchodilator FEV(1) greater than or equal to 60% of predicted. During the 6 weeks prior to enrollment, patients should have stable asthma as defined by the absence of unscheduled health care visits for asthma care and unchanged use of asthma maintenance therapy. Additional criteria for disease stability include the absence of hospitalization for asthma or the need for a course of oral corticosteroids during the preceding 3 months. Research subjects must have a positive skin test to a common aeroallergen, such as dust mite, cat, short ragweed, cockroach, or grass or a prior history of severe allergy or anaphylaxis. Chest radiograph without evidence of pulmonary disease, other than asthma. Left ventricular ejection fraction greater than or equal to 50% by echocardiogram. For women of childbearing potential, negative pregnancy test within 2 weeks prior to study and willingness to adhere to reliable birth control methods during the study. Subjects with a history of dermatologic cancers may be included if they have been cancer-free for at least 5 years prior to enrollment. EXCLUSION CRITERIA: A known history of hypersensitivity to pioglitazone. Maintenance asthma therapy with oral corticosteroids, xolair (anti-IgE), methotrexate, cytoxan, gold salts, or cyclosporine. Cigarette smoking within the past 3 months or a prior history of greater than 10 cumulative pack-years. Viral or bacterial upper respiratory tract infection within 6 weeks prior to the screening visit. Investigational therapy for any indication within 1 month prior to the screening visit. History of lung disease other than asthma (i.e., COPD, sarcoidosis). History of diabetes mellitus, insulin secreting tumor, or symptomatic hypoglycemia. HIV or other known immunodeficiency. History of congestive heart failure. Preexisting edema (2 plus or greater). Hemoglobin less than 12 gm/dl for males and less than 11 gm/dl for females. History of liver disease or abnormal liver function tests greater than 2 times upper limit of normal. History of inflammatory bowel disease. History of cancer (other than dermatologic cancer). History of drug or alcohol abuse. Use of the following medications, which can interact with pioglitazone: Gemfibrizol (Lopid) Atazanivir (Reyataz) Ritonavir (Norvir) Rifampin (Rifampicin) Carbamzepine (Tegretol) Phenobarbital (Luminal) Phenytoin (Dilantin) Rifapentine (Priftin) Secobarbital (Seconal) Amiodarone (Cordarone, Pacerone) Palitaxel (Taxol) Replaglinide (Prandine) Ketoconazole (Nizoral) Atorvastatin (Lipitor(Registered Trademark)) Nifedipine ER (Adalat CC) Any condition that, in the investigator's opinion, places the patient at undue risk for complications from pioglitazone therapy. Dexa bone scan (T score below -1 SD). |
Country | Name | City | State |
---|---|---|---|
United States | National Institutes of Health Clinical Center, 9000 Rockville Pike | Bethesda | Maryland |
United States | Fairfax Hospital | Falls Church | Virginia |
Lead Sponsor | Collaborator |
---|---|
National Heart, Lung, and Blood Institute (NHLBI) |
United States,
Rhen T, Cidlowski JA. Antiinflammatory action of glucocorticoids--new mechanisms for old drugs. N Engl J Med. 2005 Oct 20;353(16):1711-23. Review. — View Citation
Strunk RC, Bloomberg GR. Omalizumab for asthma. N Engl J Med. 2006 Jun 22;354(25):2689-95. Review. — View Citation
Wenzel SE. Asthma: defining of the persistent adult phenotypes. Lancet. 2006 Aug 26;368(9537):804-13. Review. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | The change in post-bronchodilator FEV1. | 10 weeks | ||
Secondary | Airway inflammation, Airflow Obstruction, Airway Hyperreactivity, Asthma Symptoms, Rate of mild exacerbation, Rate of severe exacerbation, Asthma Quality-of-life, Blood Eosinophil Counts, Serum IgE and Exhaled Nitric Oxide Levels. | 10 weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT04410523 -
Study of Efficacy and Safety of CSJ117 in Patients With Severe Uncontrolled Asthma
|
Phase 2 | |
Completed |
NCT04624425 -
Additional Effects of Segmental Breathing In Asthma
|
N/A | |
Active, not recruiting |
NCT03927820 -
A Pharmacist-Led Intervention to Increase Inhaler Access and Reduce Hospital Readmissions (PILLAR)
|
N/A | |
Completed |
NCT04617015 -
Defining and Treating Depression-related Asthma
|
Early Phase 1 | |
Recruiting |
NCT03694158 -
Investigating Dupilumab's Effect in Asthma by Genotype
|
Phase 4 | |
Terminated |
NCT04946318 -
Study of Safety of CSJ117 in Participants With Moderate to Severe Uncontrolled Asthma
|
Phase 2 | |
Completed |
NCT04450108 -
Vivatmo Pro™ for Fractional Exhaled Nitric Oxide (FeNO) Monitoring in U.S. Asthmatic Patients
|
N/A | |
Completed |
NCT03086460 -
A Dose Ranging Study With CHF 1531 in Subjects With Asthma (FLASH)
|
Phase 2 | |
Completed |
NCT01160224 -
Oral GW766944 (Oral CCR3 Antagonist)
|
Phase 2 | |
Completed |
NCT03186209 -
Efficacy and Safety Study of Benralizumab in Patients With Uncontrolled Asthma on Medium to High Dose Inhaled Corticosteroid Plus LABA (MIRACLE)
|
Phase 3 | |
Completed |
NCT02502734 -
Effect of Inhaled Fluticasone Furoate on Short-term Growth in Paediatric Subjects With Asthma
|
Phase 3 | |
Completed |
NCT01715844 -
L-Citrulline Supplementation Pilot Study for Overweight Late Onset Asthmatics
|
Phase 1 | |
Terminated |
NCT04993443 -
First-In-Human Study to Evaluate the Safety, Tolerability, Immunogenicity, and Pharmacokinetics of LQ036
|
Phase 1 | |
Completed |
NCT02787863 -
Clinical and Immunological Efficiency of Bacterial Vaccines at Adult Patients With Bronchopulmonary Pathology
|
Phase 4 | |
Recruiting |
NCT06033833 -
Long-term Safety and Efficacy Evaluation of Subcutaneous Amlitelimab in Adult Participants With Moderate-to-severe Asthma Who Completed Treatment Period of Previous Amlitelimab Asthma Clinical Study
|
Phase 2 | |
Completed |
NCT03257995 -
Pharmacodynamics, Safety, Tolerability, and Pharmacokinetics of Two Orally Inhaled Indacaterol Salts in Adult Subjects With Asthma.
|
Phase 2 | |
Completed |
NCT02212483 -
Clinical Effectiveness and Economical Impact of Medical Indoor Environment Counselors Visiting Homes of Asthma Patients
|
N/A | |
Recruiting |
NCT04872309 -
MUlti-nuclear MR Imaging Investigation of Respiratory Disease-associated CHanges in Lung Physiology
|
||
Withdrawn |
NCT01468805 -
Childhood Asthma Reduction Study
|
N/A | |
Recruiting |
NCT05145894 -
Differentiation of Asthma/COPD Exacerbation and Stable State Using Automated Lung Sound Analysis With LungPass Device
|